UCB (OTCMKTS:UCBJF) Reaches New 12-Month High - Here's Why

Key Points

• UCB SA's stock price reached a new 12-month high of $253.69 during mid-day trading, up from a previous close of $248.40.
• Morgan Stanley reaffirmed an "overweight" rating for UCB, contributing to a consensus "Buy" rating from analysts.
• The company's focus includes treatments for various neurological and immunology diseases, with notable products such as Cimzia and Vimpat.

Shares of UCB SA (OTCMKTS:UCBJF - Get Free Report) hit a new 52-week high during trading on Thursday . The company traded as high as $253.69 and last traded at $253.69, with a volume of 65 shares trading hands. The stock had previously closed at $248.40.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley reiterated an "overweight" rating on shares of UCB in a research note on Monday, September 8th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, UCB currently has a consensus rating of "Buy".

UCB Stock Down 5.6%

The business's 50 day moving average price is $224.03 and its 200-day moving average price is $193.54. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.